Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 24:12:753319.
doi: 10.3389/fimmu.2021.753319. eCollection 2021.

Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol

Roos S G Sablerolles  1   2 , Abraham Goorhuis  3   4 , Corine H GeurtsvanKessel  5 , Rory D de Vries  5 , Anke L W Huckriede  6 , Marion P G Koopmans  5 , Melvin Lafeber  1 , Douwe F Postma  7 , Debbie van Baarle  6   8 , Leo G Visser  9 , Virgil A S H Dalm  10 , Neeltje A Kootstra  11 , Wim J R Rietdijk  2 , P Hugo M van der Kuy  2
Affiliations

Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol

Roos S G Sablerolles et al. Front Immunol. .
No abstract available

Keywords: Ad26.Cov2.S; BNT162.b2; COVID-19; Heterologous vaccine regimen; Homologous vaccination regimen; SARS-CoV-2; mRNA1273; randomized clinical trial.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
SWITCH trial design. The SWITCH trial includes four arms that receive a booster vaccination 84 days after prime with Ad26.COV2.S. Blood samples will be collected at indicated timepoints by venepunctures. Questionnaires will be performed to collect reactogenicity data and to determine whether participants had breakthrough infections despite vaccinations. *One of the four arms or 25% of the randomized participants will not receive a second vaccination; **Unblinding the randomization of participants will be done after the side effects (i.e., reactogenicity) questionnaire is completed.
See this image and copyright information in PMC

References

    1. Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med (2021) 384(19):1824–35. doi: 10.1056/NEJMoa2034201 - DOI - PMC - PubMed
    1. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and Efficacy of the Chadox1 Ncov-19 Vaccine (AZD1222) Against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK. Lancet (2021) 397:99–111. doi: 10.1016/S0140-6736(20)32661-1 - DOI - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med (2021) 384(5):403–16. doi: 10.1056/NEJMoa2035389 - DOI - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med (2020) 383(27):2603–15. doi: 10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Ledford H. Could Mixing COVID Vaccines Boost Immune Response? Nature (2021) 590:375–6. doi: 10.1038/d41586-021-00315-5 - DOI - PubMed

Publication types

Supplementary concepts